Molecular Imaging and Therapy

Projects

Projects per year 2010 2019 2020 2021 2022 2024 2029

• 23 Finished
• 40 Active

Projects per year

Search results

• Finished

  ANI368: Creation of a 3D CRiMe scene to unravel Cytotoxicity Resistant Mechanisms in nonsmall cell lung cancer

  De Ridder, K. & Goyvaerts, C.

  1/11/23 → 31/10/24

  Project: Fundamental

  • Non-Small Cell Lung Carcinoma 100%
  • Neoplasms 24%
  • Cytotoxic T-Lymphocytes 20%
  • Immunotherapy 16%
  • Reverse Genetics 8%

• ANI327: Putting lung cancer cells on the RADar for immunotherapy

  Goyvaerts, C. & Benoot, T.

  1/11/22 → 31/10/23

  Project: Fundamental

  • Immunotherapy 100%
  • Lung Neoplasms 79%
  • Non-Small Cell Lung Carcinoma 33%
  • Neoplasms 24%
  • Glycoproteins 21%

• ANI331: Development of specific immunotracers against CD8 and/or CD69 for non-invasive imaging of immune responses during anti-cancer immunotherapy

  Devoogdt, N. & De Pauw, T.

  1/11/22 → 31/10/23

  Project: Fundamental

  • Immunotherapy 100%
  • Neoplasms 30%
  • Single-Domain Antibodies 28%
  • Cytotoxic T-Lymphocytes 20%
  • Immune System 15%

• IOFACC9B: IOF Accelerator:Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)

  Lahoutte, T., Devoogdt, N., Keyaerts, M., Van Ginderachter, J., Laoui, D., Raes, G., Breckpot, K. & Goyvaerts, C.

  1/10/22 → 31/03/24

  Project: Applied

  • Immunotherapy 100%
  • Molecular Imaging 66%
  • Allergy and Immunology 60%
  • Physiologic Monitoring 60%
  • Drug Development 53%

• IOFACC10B: IOF Accelerator: “FLT imaging using Nanobodies: effective tool for life sciences and medical applications (NLITE)

  Lahoutte, T., Hernot, S., Kuijk, M. & Ingelberts, H.

  1/10/22 → 2/03/24

  Project: Applied

  • Single-Domain Antibodies 100%
  • Colorectal Neoplasms 32%
  • Computer-Assisted Surgery 18%
  • Biological Science Disciplines 16%
  • Costs and Cost Analysis 16%

• AIIFUND111: Validation of fluorescent anti-uPAR nanobody in an orthotopic xenograft tumor model

  Hernot, S. & Mateusiak, L.

  7/02/22 → 31/08/23

  Project: Fundamental

  • Single-Domain Antibodies 100%
  • Heterografts 60%
  • neoplasms 51%
  • image analysis 37%
  • quality of life 26%

• OZR3808: EUTOPIA Young Leaders Academy fellowship

  Goyvaerts, C.

  1/10/21 → 30/09/23

  Project: Fundamental

  • education 100%
  • academy 87%
  • budget 78%
  • duration 62%
  • leader 62%

• FWOAL1026: ERA-NET RUS.PLUS - JTC 2019: NANOtechnological TOolkit for multiplexed 3D detection and monitoring of BIOmarker status in breast cancer biopsies

  Hernot, S.

  1/07/21 → 30/06/24

  Project: Fundamental

  • Biopsy 100%
  • Biomarkers 85%
  • Tumors 39%
  • Nanoprobes 27%
  • Monitoring 25%

• FWOIRI7: FB-III (“FB triple-I”) : Flanders BioImaging: Integrating Imaging Infrastructure from cell to man.

  Lahoutte, T.

  1/02/21 → 31/01/23

  Project: Fundamental

  • Imaging techniques 100%
  • Optical microscopy 23%
  • Freight transportation 23%
  • Animals 21%
  • Information management 20%

• FWOSB112: CONVICT: sentencing Cancer cells to death through ONcolytic Virotherapy and modulation of the Immune Checkpoint TIGIT

  Zeven, K. & Devoogdt, N.

  1/11/20 → 31/10/24

  Project: Fundamental

  • Single-Domain Antibodies 100%
  • Oncolytic Virotherapy 61%
  • Neoplasms 40%
  • Prosthetic Group 38%
  • Radionuclides 36%

• EUAR33: H2020: CSA: EURAMED rocc-n-roll: title EURopeAn MEDical application and Radiation prOteCtion Concept: strategic research agenda aNd ROadmap interLinking to heaLth and digitisation aspects

  Muylle, K. & Lahoutte, T.

  1/09/20 → 31/08/23

  Project: Fundamental

  • Radiation protection 100%
  • Medical applications 52%
  • Ionizing radiation 33%
  • Analog to digital conversion 26%
  • European Union 26%

• OZR3685: H2020: CSA: EURAMED rocc-n-roll: title EURopeAn MEDical application and Radiation prOteCtion Concept: strategic research agenda aNd ROadmap interLinking to heaLth and digitisation aspects (OZR EU BONUS)

  Muylle, K. & Lahoutte, T.

  1/09/20 → 31/08/23

  Project: Fundamental

  • radiation protection 100%
  • EU 54%
  • health 34%
  • ionizing radiation 26%
  • platforms 21%

• BRGRD44: Joint R&D 2020: "IMPACT: Invigorating precision Medicine by Predictive imaging of sdAb-based anti-Cancer Theranostics"

  Lahoutte, T., Keyaerts, M., Krasniqi, A., Breckpot, K. & Goyvaerts, C.

  1/07/20 → 30/06/24

  Project: Applied

  • folate receptors 100%
  • positron-emission tomography 88%
  • Theranostic Nanomedicine 73%
  • image analysis 68%
  • Single-Domain Antibodies 61%

• ANI249: CCR8 blockade for the improvement of immunotherapy in non-small cell lung carcinoma

  Van Ginderachter, J., Devoogdt, N., Laoui, D. & Van Damme, H.

  1/04/20 → 31/03/24

  Project: Fundamental

  • Non-Small Cell Lung Carcinoma 100%
  • Immunotherapy 79%
  • Contracts 65%
  • Neoplasms 18%
  • Tumor Microenvironment 14%

• FWOAL951: Unraveling kidney clearance mechanisms of nanobodies

  Hernot, S. & Bridoux, J.

  1/01/20 → 31/12/23

  Project: Fundamental

  • Single-Domain Antibodies 100%
  • Kidney 52%
  • Radiopharmaceutical 41%
  • Radiopharmaceuticals 40%
  • Molecular Weight 28%

• FWOAL963: Evaluation of an anti-idiotype NanoCAR-T cell approach for the treatment of Multiple Myeloma

  Devoogdt, N., De Veirman, K. & Vandekerckhove, B.

  1/01/20 → 31/12/23

  Project: Fundamental

  • Single-Domain Antibodies 100%
  • Multiple Myeloma 61%
  • Radioisotopes 39%
  • Immunoglobulin Fragments 32%
  • Actinium-225 31%

• FWOSB81: Eccentric: Enhancing the function of Cancer Countering Effector cells using Nanobodies Targeting Regulatory Immune Checkpoints

  Breckpot, K., Devoogdt, N., Keyaerts, M. & Awad, R. M.

  1/11/19 → 31/10/23

  Project: Fundamental

  • Single-Domain Antibodies 100%
  • Monoclonal Antibodies 21%
  • Neoplasms 20%
  • avelumab 17%
  • Ligands 12%

• FWOSB80: Combining targeted radionuclide therapy and cancer immunotherapy to advance precision medicine through innovation.

  Breckpot, K., Devoogdt, N., D'Huyvetter, M., Keyaerts, M. & Ertveldt, T.

  1/11/19 → 31/10/23

  Project: Fundamental

  • Single-Domain Antibodies 100%
  • Radioisotopes 48%
  • Actinium-225 30%
  • Tumor Microenvironment 20%
  • Immunomodulation 17%

• FWOSB74: Intra-operative imaging in prostate and cervical cancer surgery using fluorescently-labelled nanobodies.

  Hernot, S., Devoogdt, N. & Declerck, N.

  1/11/19 → 31/10/23

  Project: Fundamental

  • Single-Domain Antibodies 100%
  • Computer-Assisted Surgery 61%
  • Label 58%
  • Fluorescence 52%
  • Clearance 36%

• EUAR14: H2020: Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies.

  Lahoutte, T., Devoogdt, N., Keyaerts, M. & De Jonge, J.

  1/10/19 → 30/09/24

  Project: Applied

  • Single-Domain Antibodies 100%
  • Immunosuppressive Agents 56%
  • image analysis 55%
  • Macrophages 47%
  • funding 37%

• SRP62: SRP-Groeifinanciering: Single-domain antibody fragment (SdAb)-based TArgeted Radionuclide Therapy: STaRT programme

  Keyaerts, M., D'Huyvetter, M. & Neyns, B.

  1/03/19 → 30/09/24

  Project: Fundamental

  • Single-Domain Antibodies 100%
  • Immunoglobulin Fragments 57%
  • Radiopharmaceuticals 54%
  • Radioisotopes 46%
  • Kidney 44%

• FWOSB58: Development of a NanoCAR-T cell approach for the treatment of multiple myeloma

  Hanssens, H., Devoogdt, N., De Veirman, K. & Breckpot, K.

  1/01/19 → 31/12/23

  Project: Fundamental

  • Chimeric Antigen Receptors 100%
  • Fees and Charges 92%
  • T-Lymphocytes 85%
  • Multiple Myeloma 73%
  • T-cells 73%

• HERC43: FWO Hercules MZW: Platform for cell analysis after radioactivity based Molecular Imaging and targeted Therapy of cancer (PeRMIT)

  Keyaerts, M., Breckpot, K., De Veirman, K. & Van Ginderachter, J.

  1/05/18 → 30/04/23

  Project: Fundamental

  • Single-Domain Antibodies 100%
  • Positron 49%
  • Immunoglobulin Fragments 45%
  • Radioisotopes 43%
  • Lysine 31%